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Calcimimetics increase the sensitivity of the parathyroid
calcium-sensing receptor to extracellular calcium for efficient
control of hyperparathyroidism. Recent studies suggest that
there are beneficial effects of calcimimetics beyond the
control of bone and mineral homeostasis. Here, we tested
whether the calcium-sensing receptor is also expressed and
functionally relevant in podocytes. Analysis of microarray
data using Gene Set Enrichment Analysis found that the
calcimimetic R-568 influenced various pathways related to
oxidative stress, cytoskeletal regulation, cell proliferation, and
survival in cultured podocytes. R-568 induced a dose- and
time-dependent phosphorylation of the ERK1/2–P90RSK–
CREB signaling cascade, and induced pro-survival
phosphorylation of BAD and Bcl-xl, thus reducing puromycin
aminonucleoside (PAN)-induced podocyte apoptosis by half.
Moreover, R-568 preserved the actin cytoskeleton in
podocytes exposed to PAN and improved recovery from
exposure to cytochalasin D, a reversible inhibitor of actin
polymerization. In rats, co-administration of R-568 prevented
the proteinuria caused by a single dose of PAN and
attenuated the glomerulosclerosis and loss of GFR caused by
repetitive puromycin treatment. Hence, calcimimetics limit
podocyte damage by antiapoptotic and cytoskeleton-
stabilizing effects and may constitute a new approach in the
prevention and treatment of glomerular disease.
Kidney International (2011) 80, 483–492; doi:10.1038/ki.2011.105;
published online 20 April 2011
KEYWORDS: apoptosis; calcium-sensing receptor; glomerulosclerosis; podocyte
The G protein-coupled calcium-sensing receptor (CaSR) is
expressed by parathyroid hormone (PTH)-producing cells
and by cells lining the kidney tubule. It has an essential role in
maintaining calcium homeostasis by sensing alterations of
circulating calcium concentrations and coupling the infor-
mation to pathways that modify PTH secretion or renal
cation handling. Mutations in the CaSR gene may cause
hypocalciuric hypercalcemia, hypoparathyroidism, or hyper-
parathyroidism. The CaSR is also involved in the regulation
of various cellular functions such as cellular proliferation,1
differentiation,2 membrane voltage,3 and apoptosis.4,5 Extra-
cellular signal-regulated kinase, mitogen-activated protein
kinases,6,7 intracellular calcium,8 phospholipase,5,7 and
potassium channels9 have been reported to mediate the
CaSR effect. Furthermore, the CaSR binds to filamin A
through its carboxy-terminal domain. Filamin A, an actin
cross-linking protein, provides mechanical strength to the
actin cytoskeleton.10,11 In glomerular visceral epithelial cells
(podocytes), the actin cytoskeleton is a highly dynamic
contractile apparatus critical for the integrity of the cells’
characteristic foot processes. Alterations of the actin
cytoskeleton lead to reversible foot-process effacement and
proteinuria, followed by podocyte apoptosis and eventual
irreversible glomerular sclerosis.12
Pharmacological activation of the CaSR can be achieved
by phenylalkylamine compounds such as R-568 and cina-
calcet. These agents allosterically bind to the parathyroid and
tubular CaSR, increase its sensitivity to extracellular calcium,
and reduce plasma PTH, calcium, and phosphate levels.13
Cinacalcet is the first calcimimetic approved for treatment of
uremic hyperparathyroidism. Recent animal work moreover
suggests beneficial effects of calcimimetics beyond control of
bone and mineral homeostasis. In subtotally nephrectomized
rats, the calcimimetic R-568 markedly reduced proteinuria,
blood pressure, glomerulosclerosis, and the progression of
renal failure.14 As similar findings were obtained by para-
thyroidectomy, it was assumed that the renoprotective effect
observed with calcimimetics is related to suppression of PTH
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secretion and a sustained reduction in blood pressure.15
Here, we propose a direct nephroprotective action of R-568
at the glomerular podocyte level. We demonstrate that the
CaSR is expressed by differentiated murine podocytes and its
pharmacological activation induces transcriptional and post-
translational pathways promoting cell survival and functional
integrity. Consistent with these podocyte protective actions,
R-568 is demonstrated to prevent proteinuria, reduce
glomerulosclerosis, and conserve global renal function in a
model of subacute podocyte damage.
RESULTS
The CaSR is expressed by differentiated podocytes
The CaSR was expressed both on the RNA and on the protein
level in differentiated cultured murine podocytes, but not in
cells in the undifferentiated state. Immunocytochemical and
immunogold staining of cultured podocytes showed the
CaSR to be localized at the endoplasmic reticulum (ER), the
periphery of the cytoplasm, and the cell membrane. In
addition, there was evidence for vesicular trafficking from the
ER to the cell membrane (Figure 1a). Electron microscopy
studies with immunogold labeling in mice kidney sections
demonstrated localization of the CaSR close to the slit
diaphragm of the podocytes (Figure 1b and c). Co-staining of
the CaSR and podocin in human renal tissue identified CaSR
in human podocytes (Figure 1d). CaSR abundance was
similar in murine-cultured podocytes, isolated glomeruli,
and whole kidney lysates (112±23%, 127±11%, and
121±11% of b-actin control; Figure 2a). Sucrose gradient
ultracentrifugation showed enrichment of CaSR proteins in
caveolin-poor membrane fractions (Figure 2b).
GSEA indicates that R-568 reduces oxidative stress, stabilizes
the cytoskeleton, enhances cell cycle control, and suppresses
apoptosis in podocytes
Microarray experiments and a functional analysis of micro-
array data using Gene Set Enrichment Analysis (GSEA) were
performed to reveal the impact of R-568 on podocytes. R-568
influenced various pathways related to oxidative stress, cyto-
skeletal regulation, cell proliferation, and survival (Table 1).
The gene set ‘response to oxidative stress’ was enriched by
R-568. The upregulation of glutamate cysteine ligase catalytic
subunit (Gclc) and glutamate cysteine ligase modifier subunit
(Gclm), two rate-limiting enzymes for the synthesis of
glutathione, implies a potential anti-oxidative effect of
R-568. Also, the gene set ‘regulation of cytoskeleton organi-
zation and biogenesis’ was enriched in the treated group. A
cytoskeleton-stabilizing effect of R-568 is indicated by the
upregulation of genes responsible for microtubule stabiliza-
tion (Mid1ip1, Arhgef2, Apc, Mapt and Clasp1), for actin
filament formation (Cdc42ep2 and Arf6), and for stress fiber
formation (Arhgef10l, Tsc1 and Nf2). The upregulation of
gene set ‘cell cycle arrest GO0007050’ and downregulation of
gene set ‘apoptosis_GO’ imply that R-568 enhances cell cycle
control and suppresses apoptosis in podocytes.
R-568 activates prosurvival factors through the ERK1/2
pathway
GSEA suggests that the MAPK pathway mediates the effect of
R-568 on podocytes (Table 1). We therefore examined the
response of different MAPK members to R-568 and their
impact on prosurvival genes. ERK1/2 was phosphorylated in
response to R-568 exposure in a dose- (4–50 nmol/l) and
time-dependent manner (Figure 3a and b). Increasing the
concentration above 10 nmol/l did not lead to a further
activation of ERK1/2. Maximal phosphorylation was obta-
ined after 10min of R-568 and returned to baseline within
60min. The p38MAPK showed a biphasic response pattern
with phosphorylation after 5min and again after 30min of
R-568 exposure, while the third member of the MAPK
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Figure 1 |Podocyte calcium-sensing receptor (CaSR) staining.
CaSR expression in a differentiated mouse podocyte (a,
magnification  63), in mouse kidney (b, c, electron microscopy,
immunogold labeling;  34,000 and  100,000), and in human
kidney tissue (d, immunostaining, podocin red, CaSR green,  64).
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Figure 2 |Renal calcium-sensing receptor (CaSR) abundance
and localization. CaSR abundance is similar in whole kidney
tissue lysate, isolated glomeruli and in murine cultured podocytes
(a). Sucrose density gradient centrifugation of cultured mice
podocyte, followed by western blotting, demonstrated that the
CaSR is not found in the caveolin-1 and 2 enriched membrane
fractions (b).
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family, JNK, showed no response at any time point (data not
shown).
The downstream kinase 90RSK was phosphorylated in
response to R-568 (10 nmol/l) in a similar time pattern as
ERK1/2 and led to phosphorylation of the transcriptional
factor cAMP response element binding protein (CREB;
Figure 3c), a well-established activator of prosurvival genes.
R-568 (10 nmol/l) increased the amount of pBAD in a time-
dependent manner; maximal phosphorylation occurred
within 6–12 h.
Bcl-xl was phosphorylated in a similar, time-dependent
manner by R-568 (Figure 4). The specific MEK1/2 inhibitor
(UO126, 10 mmol/l), a kinase upstream of ERK1/2, prevented
the R-568-induced phosphorylation of ERK1/2 and CREB
(Figure 5). Intracellular cAMP was dose- and time-depen-
dently reduced by R-568 (10 nmol/l, 5min: 80±16%;
P¼NS, 10min 35±13%, Po0.05; 100 nmol/l, 5min: 35±
4%, Po0.05; 10min: 34±3%, Po0,05 as compared with
untreated control). The activity of the Rho kinases RhoA and
Rac1 was increased by R-568 (þ 44±1% and þ 127±10%,
compared with untreated control, both Po0.05).
R-568 protects from puromycin aminonucleoside
(PAN)-induced apoptosis in vitro
Fluorescence-activated cell sorting analyses were performed
to prove that R-568 protects podocytes from stress-induced
apoptosis. PAN (30 mg/ml) increased apoptosis in cultured
podocytes from a baseline rate of 20% to 46±5 and 74±9%
after 48 and 60 h of incubation, respectively (Figure 6).
Addition of R-568 (10 nmol/l) reduced the PAN-induced
increase in apoptosis rate by 57±3 and 50±5% after 48 and
60 h, respectively (both Po0.05).
R-568 protects podocytes from cytoskeletal damage
Incubation of podocytes with PAN (30 mg/ml) for 72 h
resulted in cytoplasmatic shrinking, increased apoptosis, and
a partial disruption of actin filaments. Actin was localized
peripherally; focal contacts were diminished; and the cell size
and the actin content per cell were reduced (Figure 7,
Table 2). Administration of R-568 (10 nmol/l) increased cell
size, actin density, and actin content per cell. Co-incubation
with PAN and R-568 completely prevented cell shrinking,
actin depletion, and partially preserved cytoskeletal structure.
In podocytes treated with ERK1/2, p38, and JNK inhibitors,
the actin cytoskeleton appeared unaltered. The protective
action of R-568 against PAN was preserved. In contrast,
in podocytes treated with the rho-kinase inhibitor H1152,
the actin cytoskeleton was largely degraded and R-568
co-administration lost its protective effect against PAN.
Exposure of podocytes to the protein kinase A inhibitor H89
partially inhibited actin cytoskeleton formation and the
protective action of R-568 (Figure 7).
Cytochalasin D exposure (2mmol/l) for 48 h caused cell
retraction and disruption of podocyte actin filaments;
Table 1 | Cellular pathways regulated by R-568 in podocytes
Gene set NES NP FDR
Response to oxidative stress 1.657 0.002 0.045
Regulation of cytoskeleton organization and biogenesis 1.635 0.0098 0.049
Apoptosis_GO 1.512 o0.0001 0.099
Cell cycle arrest GO0007050 1.439 0.0541 0.122
Activation of JNK pathway 1.799 0.004 0.023
Regulation of MAPKKK cascade 1.743 0.0081 0.033
Abbreviations: FDR, false discovery rate; MAPKKK, kinase of the kinase of the mitogen-activated protein kinase; NES, normalized enrichment score, a positive NES value
indicates enrichment in the R-568-treated group; NP, nominal P value.
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Figure 3 |Calcimimetic R-568-induced signal transduction in
podocytes. Dose-and time-dependent phosphorylation of ERK1/2
(a, b) and time-dependent phosphorylation of cAMP response
element binding protein (CREB) (c) in response to 10 nmol/l of R-
568 (R) in podocytes. C, untreated control.
pBAD
BAD
C R C R C R C R
36 h
C R
36 h
24
C R
24
12
C R
12
6
C R
6
Bcl-xl
Figure 4 |R-568 induces prosurvival factors BAD and
Bcl-xl. Murine podocytes were treated with R-568 (10 nmol/l; R)
for 6–36 h. C, control.
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co-incubation with R-568 prevented cytoskeletal damage
(data not shown). To investigate whether R-568 also
improves actin skeleton reassembly, we treated cytochalasin
D preincubated podocytes with R-568. Addition of R-568
after 48 h of incubation with cytochalasin D significantly
accelerated actin recovery compared with cytochalasin
D-pretreated podocytes that were incubated only with medium
after cytochalasin exposure (Figure 8, Table 3). The actin
cytoskeleton was largely restored in both groups after 72h.
R-568 reduces PAN-induced proteinuria and glomerulo-
sclerosis
A single PAN injection induced severe proteinuria within 6
days (3.426±352 vs 73±3.7 g/mol creatinine in solvent-
treated controls, Po0.0001). Pre-administration of R-568
prevented the development of proteinuria (339±116 g/mol
creatinine, Po0.0001 vs PAN alone). The protective effect
persisted through day 9 (Figure 9); proteinuria disappeared
within 24 days. Partial prevention of proteinuria was
achieved when R-568 was given 2 and 4 days after PAN
injection (1.457±339 and 1.486±75 g/mol creatinine vs
4.474±303 g/mol creatinine without R-568 rescue; Po0.05
vs PAN alone).
In a subsequent experiment, Sprague–Dawley rats under-
went three sequential PAN injections at 4-week intervals, with
or without concomitant injections of R-568. Nine days after the
third PAN injection four PAN-treated animals had died,
whereas all animals in the other groups survived. The surviving
animals displayed reduced weight gain, proteinuria, hypoalbu-
minemia, hypercholesterolemia, and a markedly reduced GFR
(Table 4). Co-administration of R-568 significantly lowered
PAN-induced proteinuria and GFR loss, improved weight gain,
and tended to attenuate hypoalbuminemia.
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Figure 5 |R-568-dependent phosphorylation of ERK1/2 and
cAMP response element binding protein (CREB) is MEK-
dependent. Murine podocytes were treated with R-568
(10 nmol/l; R) for the indicated time intervals in the presence
and absence of the MEK 1/2 inhibitor U0126 (10mmol/l; I),
indices indicate the treatment time in minutes. C, control.
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Figure 6 |R-568 prevents puromycin aminonucleoside (PAN)-
induced apoptosis of podocytes. Podocytes were treated with
PAN (30 mg/ml), R-568 (10 nmol/l), and a combination of both for
48 and 60 h. The number of apoptotic cells was determined by
fluorescence-activated cell sorting. Data from 10 independent
experiments, each performed in duplicate, are given as
percentage of total cell number; *Po0.05.
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Figure 7 |R-568 mitigates puromycin aminonucleoside (PAN)-
induced cytoskeletal damage in podocytes. Incubation of
podocytes with medium, PAN (30mg/ml), R-568 (10 nmol/l), and a
combination of both for 72 h followed by specific staining for
actin, 40,6-diamidino-2-phenylindole and vinculin. Coincubation of
podocytes with PAN and R-568 preserves the cytoskeleton,
whereas PAN alone results in disruption of the cytoskeletal
structure. Inhibitors of MEK (UO126), p38 (SB203580), and JNK
(SP600125) did not interfere with the protective action of R-568,
whereas rho kinase (H1152) and, to a smaller extent, protein
kinase A inhibition (H89) inhibited actin cytoskeleton formation
and the actin-preserving action of R-568 in PAN-treated
podocytes.
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Histomorphometric assessment demonstrated signifi-
cantly fewer FSGS lesions in animals with PAN/R-568 co-
administration (glomerulosclerosis index 1.50±0.2 vs
2.47±0.4 with PAN alone, Po0.05). The glomerular
podocyte number, visualized by Wilms tumor-1 staining,
was significantly reduced in PAN-treated rats (number of
podocytes per glomerulus section 4.55±0.64) as compared
with controls (7.9±0.62, P¼ 0.01), but conserved in PAN
and R-568 co-treated rats (7.61±0.91, P¼ 0.05; vs PAN
alone, Figure 10). R-568 treatment alone had no effect on
podocyte number (7.07±1.16, NS vs control). Ten days after
R-568 treatment, glomerular pBAD abundance was not
different between groups (PAN: 128±32% and PAN þR-
568: 140±33% as compared with untreated rats, all P¼NS).
Table 2 | Cell size and actin content in podocytes
Control PAN R-568 PAN+R-568
Mean cell surface (mm2) 3043±221 1497±179a 4582±438a,b 2739±317b
Mean actin per mm2 (AU) 949±33 1110±35a 1102±49a 1126±46a
Mean actin per cell (AU  103) 2537±231 1484±168a 4769±571a,b 2585±258b
Abbreviations: AU, arbitrary units; PAN, puromycin aminonucleoside.
aPo0.05 vs control.
bPo0.05 vs PAN.
Podocytes were treated with puromycin (30 mg/ml) and R-568 (10 nmol/l) for 72 h. See Materials and Methods for details.
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Figure 8 | Improved cytoskeletal recovery in R-568-treated podocytes. Podocytes were treated with polymerization inhibitor
cytochalasin D (CD, 2 mmol/l) for 48 h. Subsequent recovery of the actin cytoskeleton was monitored by staining for actin,
40,6-diamidino-2-phenylindole and vinculin after 24 and 48 h in the presence and absence of R-568 (10 nmol/l).
Table 3 | Recovery of podocyte actin skeleton from CD treatment
Control (48h) CD (48 h) 24h after CD 24h after CD+R-568 48 h after CD 48h after CD +R-568
Mean cell surface (mm2) 2891±290 1265±108a 1498±105a 4704±329a,b,c 3409±228b,c,d 3080±337b,c,d
Mean actin per mm2 (AU) 928±38 224±14a 311±22a,b 593±19a,b,c 795±36a,b,c,d 1141±51a,b,c,d,e
Mean actin per cell (AU  103) 2688±328 284±28a 469±44a,b 2813±218b,c 2697±202b,c 3708±543b,c
Abbreviations: AU, arbitrary units; CD, cytochalasin D.
aPo0.05 vs control.
bPo0.05 vs cytochalasin D.
cPo0.05 vs 24-h recovery.
dPo0.05 vs 24-h recovery + R-568.
ePo0.05 vs 48-h recovery.
After treatment with the polymerization inhibitor cytochalasin D (2 mmol/l) for 48 h, podocytes were incubated with medium and with medium containing R-568 (10 nmol/l).
The actin cytoskeleton recovered faster in podocytes post-incubated with R-568 than in podocytes treated with medium alone.
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Phalloidin staining indicated increased glomerular actin
content with R-568 treatment. Glomerular and tubular CaSR
abundance was not influenced by R-568 treatment, but was
significantly increased in PAN-treated rats (R-568: 104±7%,
PAN: 255±37%, PAN þR-568: 253±26% vs CaSR/b-actin
ratio in solvent-treated controls, all Po0.05; (Figure 11a and b).
DISCUSSION
The growing prevalence of progressive chronic kidney
disease, a condition associated with high morbidity, excessive
mortality, and enormous costs to health systems worldwide,
creates a need for effective preventive strategies. To date,
concepts of pharmacological nephroprotection are largely
limited to tight blood pressure control and antiproteinuric
intervention using antagonists of the renin–angiotensin
system.16 In numerous kidney disorders such as diabetic
nephropathy, the most common cause of chronic renal failure
in adults, a central pathophysiological role is attributed to the
podocyte. Podocyte dysfunction and loss lead to glomerular
proteinuria, a marker and key mediator of progressive renal
damage. We set out to investigate the hypothesis that
calcimimetic compounds, in addition to their PTH-suppres-
sing and their recently detected blood pressure-lowering
effect,15 might exert direct podocyte protective actions.
A biological basis for this hypothesis was provided by the
detection of CaSR expression in rat glomeruli17 and, as
demonstrated here, in murine and human podocytes. The
protein is found both in the cytoplasm and at the cell
membrane of foot processes in the immediate vicinity of the
slit diaphragm. In podocytes, membrane-bound CaSR does
not seem to be enriched in ‘lipid raft’ domains. Localization
to these multifunctional membrane regions has been
reported in parathyroid and osteoblast-like cells, but not in
endothelial cells.18–20
Allosteric binding of R-568 to the CaSR activates several
specific intracellular signaling cascades and results in an array
of cellular responses, such as reduced parathyroid hormone
secretion from the parathyroid glands and calcium reabsorp-
tion in the kidney. Less attention has thus far been given to
other principal cell functions such as proliferation, differ-
entiation, and apoptosis.1–5 In the kidney, podocyte loss is a
critical determinant underlying the development of glomer-
ulosclerosis and progressive renal failure.
PAN exposure is an established model applicable in vivo
and in vitro to produce podocyte damage. PAN causes
oxidative stress and accelerates proliferation and apoptosis of
podocytes, which precedes glomerulosclerosis.21 Our micro-
array data suggest a nephroprotective effect of R-568 opposite
to PAN, as R-568 induces antioxidative mechanisms,
enhances cell cycle control, and suppresses apoptosis in
podocyte cell culture.
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Figure 9 |R-568 prevents puromycin aminonucleoside (PAN)-
induced proteinuria in rats. Rats received a single intraperito-
neal injection of PAN (150mg/kg body weight, hatched bars) or
solvent (white bars). In animals simultaneously receiving PAN and
R-568 (20mg/kg subcutaneously, black bars), proteinuria was
largely prevented (Po0.0001, day 6 and 9).
Table 4 | R-568 mitigates puromycin aminonucleoside (PAN)-induced nephrotic syndrome and GFR loss
Body weight
gain (g)
S-Ca
(mmol/l)
S-albumin
(g/l)
S-creatinine
(mg/dl)
S-cholesterol
(mg/dl)
Creatinine
clearance (ml/h)
U-protein
(g/mol Cr)
S-PTH
(pg/ml)
Solvent 343±8 2.3±0.1 36±1.5 0.28±0.01 49±4 211±22 102±7 168±33
R-568 348±137 2.42±0.04 38±1.2 0.32±0.01 53±4 203±38 76±4 183±66
PAN 242±11a,b 2.35±0.07 26±1.0a,b 0.75±0.16a,b 560±85a,b 29±7a,b 5719±596a,b 1740±534a,b
PAN+R-568 291±16a,b,c 2.52±0.07 30±2.4b 0.50±0.06a,b 323±58a,b,c 112±24c 3247±760a,b,c 1173±880a,b
Abbreviations: GFR, glomerular filtration rate; PTH, parathyroid hormone; S-PTH, serum parathyroid hormone.
aPo0.05 vs solvent.
bPo0.05 vs R-568.
cPo0.05 vs PAN.
Serum and urine biochemistry in rats receiving repeated injections of solvent, R-568, PAN or both, R-568 and PAN. See Materials and Methods for details.
Control
PAN PAN +
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R-568
Figure 10 |Wilms tumor-1 expression in rat kidney. Rats
received three intraperitoneal injections of R-568 (20mg/kg body
weight) or puromycin aminonucleoside (PAN, 150mg/kg) or PAN
and R-568 at monthly intervals. The number of podocytes is
preserved in PAN and R-568 co-treated rats.
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The antiapoptotic effect of R-568 is supported by its
activation of pro-survival signaling, such as the induction of
CREB, Bad, and Bcl-xl phosphorylation, which is mediated
via dose- and time-dependent stimulation of ERK1/2,
whereas cAMP abundance, in line with previously published
findings,22 was downregulated by R-568. The antiapoptotic
effect of R-568 was further confirmed in PAN-treated
podocytes. A profound antiapoptotic action of CaSR
activation has also been demonstrated in other cell types.
Virus and c-myc overexpression induced apoptosis in
prostate carcinoma and rat fibroblasts, which express the
CaSR, and can be inhibited by increasing extracellular
calcium. Stable transfection of the CaSR in human
embryonic kidney cells, otherwise not expressing the CaSR,
results in resistance to virus-induced apoptosis.
R-568 upregulated genes enhancing cell cycle arrest, which
suggests that the renoprotective effect of R-568 could be
mediated by its antiproliferative action. Calcimimetics have
previously been shown to inhibit proliferation of parathyroid
cells.23 As mature podocytes are highly differentiated post-
mitotic cells, they can regain a proliferative potential if
damaged. Podocyte proliferates contribute to extracapillary
damage in certain forms of glomerulonephritis.24
A further renoprotective mechanism of calcimimetics may
be mediated through actions on the actin cytoskeleton. The
CaSR is directly linked to the cytoskeleton by means of
binding to filamin A. In podocytes, the actin cytoskeleton
forms a highly dynamic contractile apparatus critical for
podocyte foot process integrity. Alterations of the podocytic
actin cytoskeleton result in foot process effacement, protei-
nuria, apoptosis, and irreversible glomerular sclerosis.12 We
noted a major cytoskeleton-stabilizing effect of R-568 in
podocytes exposed to PAN. This cytoskeleton-preserving
action of R-568 was independent of MAP kinase activity,
but was abolished when rho kinases were blocked. The
protective effect was partially blocked also by the protein
kinase A inhibitor H89; this effect might be explained
by inhibition of the rho kinases, which are also affected
by H89.25
Furthermore, we demonstrate an improved recovery of the
actin cytoskeleton on exposure to the cytoskeleton disrupting
toxin cytochalasin D. Microarray analysis confirmed that the
calcimimetic induces the transcriptional machinery required to
stabilize microtubules and form actin filament and stress fibers.
The in vitro findings in support of a podocyte protective
action of calcimimetics were confirmed by our in vivo
experiments. The applied in vivo model of PAN-induced
podocyte injury has been well characterized. Following a
single PAN injection, rat podocytes manifest a loss
of interdigitating foot processes, detachment from the
glomerular basement membrane, pseudocyst formation,
reduction in anionic charge, attenuation of the underlying
glomerular basement membrane, and associated leakiness of
the glomerular filter, resulting in proteinuria and minor
glomerulosclerosis.21 Repeated administration of PAN leads
to a patchy glomerular scarring process, that is, focal
segmental glomerulosclerosis as seen in humans with
progressive proteinuric glomerular disease. Using this model
of podocyte and glomerular injury, we demonstrate that
R-568 not only prevents proteinuria following a single PAN
injection, but also mitigates the structural damage induced by
repetitive PAN exposure. The protective effect was evident by
an unchanged podocyte number per glomerulus and reduced
glomerular sclerosis. These effects are similar to those
observed with glucocorticoids26 and most likely independent
of the effects of calcimimetics on PTH. The R-568 injection at
the given dose only results in transient decreases in PTH and
ionized calcium for 24 h.27 At the time of sacrifice, serum
PTH and calcium were similar in R-568 and control groups.
The previously reported beneficial effects of R-568 on
glomerular morphology and function in subtotally nephrec-
tomized rats14 have been ascribed to the PTH-lowering effect
of the calcimimetic, as parathyroidectomy resulted in similar
findings in this rat model of renal failure. Here we
demonstrate a direct action of the calcimimetic in a PTH-
independent model of renal damage.
In summary, we report a direct renoprotective action of
the calcimimetic R-568, which exerts pro-survival signaling
and genomic actions and stabilizes the actin cytoskeleton in
podocytes and attenuates glomerular damage in vivo. Given
their good tolerability and few side effects, the use of
calcimimetics may be a promising new approach in pharma-
cological nephroprotection.
Solvent
PAN
CaSR 130 kDa
β-Actin 42 kDa
Control R-568 PAN PAN+R-568
PAN+
R-568
R-568
Negative
control
Figure 11 |Calcium-sensing receptor (CaSR) expression in rat
kidney. Rats received three intraperitoneal injections of
R-568 (20mg/kg body weight) or puromycin aminonucleoside
(PAN, 150mg/kg) or PAN and R-568 at monthly intervals.
Immunohistochemistry (a) and western immunoblotting
(b) demonstrate increased glomerular and tubular CaSR
expression in response to PAN.
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MATERIALS AND METHODS
Cell culture
Conditionally immortalized murine podocytes generated from the
ImmortoMouse (Charles River, Wilmington, MA) carrying a tempera-
ture-sensitive T-antigen as transgene under the control of an
interferon-g inducible promoter were maintained cultured as de-
scribed.28 To induce differentiation, podocytes were grown on collagen
type I (BD Biosciences, Bedford, MA) under permissive conditions at
33 1C with interferon-g (10U/ml) (Roche, Mannheim, Germany) or
under non-permissive conditions at 37 1C without interferon-g for at
least 10 days. Podocytes were treated with R-568 (Amgen, Thousand
Oaks, CA). Podocyte injury was induced by treatment with PAN
(Sigma, St Louis, MO) dissolved in 0.9% cyclodextrin.
Electron microscopy and immunogold labeling
Ultrathin frozen sections of perfusion-fixed mouse kidney were
incubated first with rabbit anti-CaSR antibody (Alpha Diagnostics,
San Antonio, TX), followed by a gold-conjugated anti-rabbit
secondary antibody. Transmission electron microscopy and im-
munoelectron microscopy were performed according to standard
protocols.29 Cultured podocytes were incubated with an anti-CaSR
antibody (Affinity BioReagents, Golden, CO), followed by a gold-
conjugated anti-rabbit secondary antibody.
Preparation of caveolin-enriched fraction
Caveolae-rich membrane fractions from podocytes were obtained by
sucrose gradient ultracentrifugation.30 In brief, podocytes were
homogenized in 2ml of lysis buffer (10nmol/l Tris-HCl, pH 7.5,
150nmol/l NaCl, 5mmol/l EDTA, 1mmol/l phenylmethylsulfonyl
fluoride, 10mg/ml leupeptin, 10mg/ml trypsin inhibitor, and 1% Triton
X-100) followed by sonification. The homogenate was brought to 40%
sucrose by addition of an equal volume of 80% sucrose and loaded into
an ultracentrifuge tube. A discontinuous sucrose gradient was layered
on top of the sample by placing 4ml of 30% and 4ml of 5% sucrose,
respectively. After centrifugation at 200 000g for 24h at 4 1C, 12 1-ml
fractions were collected and analyzed by western blot.
Microarray procedure and pathway analysis
RNA extraction, reverse transcription of 10 mg RNA, complementary
RNA synthesis and labeling, as well as hybridization to the
microarray type Moe430_2 (Affymetrix, Santa Clara, CA) were
performed using standard Affymetrix protocols. Quantile normal-
ization and background subtraction were performed to generate
base 2 log-transformed expression values for all probe sets. The
Moe430_2 microarray contains probe sets to monitor the expression
of 21 891 annotated mouse genes. A total of six arrays were
hybridized, three for each podocyte culture treated with R-568 or
solvent. Microarray data were reported to GEO, GSE 15761.
To detect the pathways regulated by R-568, microarray data were
analyzed at the functional group level, using Gene Set Enrichment
Analysis (GSEA).31 GSEA was performed with probe-level rather
than gene-level data. To circumvent the problem of probe effects,
that is, different characteristics of different probes for the same gene
during array hybridization, the mean of each probe across arrays was
subtracted from the probe-level data. All GO gene sets listed in
Molecular Signatures Database were subjected to GSEA, with 1000
permutations on phenotype.
Real-time RT-PCR
RNA was isolated with RNeasy Mini Kit (Qiagen, Hilden, Germany),
checked for integrity on an agarose gel, and quantified photometrically
(Biophotometer, Hamburg, Germany). One microgram of total
RNA was reverse transcribed with poly (dT)/random hexamer
primers (1:10). Real-time RT-PCR was performed with the ABI
Prism 7000 sequence detection system (Applied Biosystems,
Darmstadt, Germany) with primers specific for 18 s. Real-time RT-
PCR for mouse podocytes was performed using specific primers
(MWG-Biotech AG, Ebersberg, Germany) and Sybr Green Master-
mix (Eurogentec, Cologne, Germany).
Tissue extraction and western blotting
Protein extraction from cultured podocytes and SDS-polyacryla-
mide gel electrophoresis were done as described previously.28
Glomeruli were extracted from mouse renal tissue by sieving
techniques. Total and phosphorylated proteins were detected by
western blotting as described elsewhere,28,32 using the following
primary antibodies: Bad (Bcl2-associated agonist of cell death,
1:1000), pBad (1:750), Bcl-xl (B-cell chronic lymphocytic leukemia/
lymphoma 2-xl, 1:500), CREB (1:2000), ERK1/2 (1:4000), pERK 1/2
(1:2000), pJNK (1:1000), pMAPK38 (1:500), p90RSK (1:2000) (all
from Cell Signaling Technology, Beverly, MA), Bcl-2 (1:1000),
Caveolin-1 (1:500), b-actin (1:10,000) (all from Abcam, Cambridge,
UK), and CaSR 1:100 (Alpha Diagnostics). Western blot analysis was
carried out according to standard protocols and visualized using
enhanced chemiluminescence immunoblot detection kits (Amer-
sham Biosciences, Buckinghamshire, UK). RhoA and Rac1 kinases
were determined by an Activation Assay Combo Kit (Cell Biolabs,
San Diego, CA), and cAMP was measured by evaporation of cell
lysates followed by Radio Immuno Assay (Immundiagnostik,
Bensheim, Germany).
Immunohistochemistry
Immunofluorescence staining was performed on 4-mm frozen
sections from rat kidney and cultured podocytes growing on
collagen type I-coated glass cover-slips after fixation with 4%
paraformaldehyde as described previously.33 To localize CaSR, we
used a specific CaSR1-antibody (1:100, Affinity BioReagents #PA-1),
and Synaptopodin G1 (1:200). The following secondary antibodies
were used: Alexa Fluor 488 IgG1þ IgG3 1:1000 (Molecular Probes,
Invitrogen, Eugene, OR) and Alexa Fluor 546 (Mol Probes,
Invitrogen, Carlsbad, CA) (1:3000). To determine the number of
podocytes per glomerulus, Wilms tumor-1 staining was performed
with a specific antibody (Santa Cruz Biotechnology, Santa Cruz,
CA). Fifty glomeruli per animal were analyzed. Podocin was stained
with a specific podocin antibody (Sigma). Tumor-free human renal
tissue was obtained from six patients from a biobank of the National
Center for Tumor Diseases Heidelberg; ethical approval was
obtained from the local ethics committee.
Flow-cytometric detection of apoptosis
Cells were washed with phosphate-buffered saline and trypsinized.
All washes and diluted cells were collected, pooled, centrifuged, and
resuspended in a fluorescence-activated cell sorting buffer (2%
bovine serum albumin in phosphate-buffered saline, pH 7.4). After
incubation with an annexin-binding buffer and propidium iodide
(Molecular Probes, Carlsbad, CA) for 45min, cells were centrifuged
and resuspended in annexin-binding buffer. Annexin-V binds
phosphatidylserine, which is translocated to the outer cell
membrane during the initial stages of apoptosis. Propidium iodide
was also applied to cells in order to distinguish necrosis from
apoptosis. Cells were analyzed by flow cytometry (FACScalibur,
Becton Dickinson, Franklin Lakes, NJ). Apoptosis-associated
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fluorescence was measured using a log scale. Cells with high propidium
iodide content were necrotic and were excluded from the analysis.
Actin depolymerization and recovery studies
The in vitro PAN model of podocyte process retraction used for these
studies was performed as previously reported,34 with minor modifica-
tions. Briefly, cells were treated for 72h with PAN (30mg/ml, Sigma)
alone or in combination with R-568 (10nmol/ml). In addition, cells
were treated with intracellular signaling inhibitors alone or in combi-
nation with PAN and R-568 (protein kinase A inhibitor H89, 10mmol/l;
Rock inhibitor H-1152, 1mmol/l; MEK-inhibitor UO126, 10mmol/l;
P38-inhibitor SB203580, 10mmol/l; and JNK inhibitor SP600125,
5mmol/l; all inhibitors were obtained from Calbiochem, Darmstadt,
Germany). Cells were subsequently fixated and stained with specific
phalloidin and vinculin antibodies and 40,6-diamidino-2-phenylindole.
For the recovery experiments, podocytes were treated with the
actin cytoskeleton-disrupting agent cytochalasin D (2mmol/l, Sigma)
for 48 h alone or in combination with R-568. After pretreatment, the
culture medium was replaced with fresh medium and recovery of the
actin cytoskeleton was monitored. Actin was stained by rhodamine-
labelled phalloidin (Invitrogen, Carlsbad, CA), vinculin by a specific
antibody (Sigma Aldrich, St Louis, MO), nuclei with 40,6-diamidino-
2-phenylindole (Serva GmbH, Heidelberg, Germany) and was digi-
talized using a confocal microscope (Leica TSL, Leica Microsystems,
Germany). Rhodamine-stained areas of actin fibers were converted
into black pixels, then inverted and quantified by ImageJ (NIH,
Bethesda, MD). Gray scale values ranged from 0 (black) to 200 (white;
maximal actin content). Podocyte mean actin per pixel and total actin
content per cell were calculated and given as arbitrary units.
In vivo experiments
Male Sprague–Dawley rats (Charles River Laboratories, Sulzfeld,
Germany) weighing approximately 80–100 g were kept individually
in a room controlled for light (12 h on/off cycles), temperature
(24 1C), and humidity (70%). The animals had free access to a
standard diet (ssniff R/M-H; Ssniff, Soest, Germany) and tap water.
The animal experimentation and handling were in accordance with
the German law for protection of animals.
Single PAN injection experiment
Animals were assigned to the treatment groups according to body
weight, and treated with a single intraperitoneal. injection of PAN
(150mg per kg body weight PAN, dissolved in 0.9% cyclodextrin),
R-568 (20mg/kg body weight subcutaneously), an equivalent
volume of 0.9% saline, and a combination of both PAN and
R-568, respectively. R-568 was administered 4 h prior to PAN. The
number of animals per group was 10–15. 24-h urine was collected in
metabolic cages on days 3, 6, and 9. On day 9, rats were killed. The
left kidney was removed and fixed in glutaraldehyde solution; the
right kidney was perfused with paraformaldehyde in phosphate
buffer for 8min at a pressure of 120mmHg. After perfusion,
kidneys were quickly removed, and 3–4mm sections were cut for
fixation in formalin. The glomerulosclerosis index was assessed on
PAS-stained paraffin sections according to a semiquantitative
scoring system (scores 0–4) by an observer blinded to the group
assignment of the samples. Protein/creatinine ratio was measured
with ADVIA 2400 (Bayer Diagnostics, Leverkusen, Germany).
Repeated PAN injection experiment
In a second experiment, rats (n¼ 8–10 per group) received three
sequential injections of PAN (150mg/kg) with or without R-568
(20mg/kg body weight subcutaneously) at 30-day intervals. 24-h
urine collections for proteinuria and creatinine clearance were
obtained 6 days after the third PAN and R-568 injections. On day 70,
that is 10 days after the last injections, all animals were killed and
tissues and blood samples were collected as described. All animal
experimentation and handling were in accordance with the German
law for protection of animals. Rat PTH was measured using an
intact-PTH enzyme-linked immunosorbent assay with 3% intra-
and 8% inter-individual coefficient of variation (Immutopics, San
Clemente, CA).
Statistics
Data are given as mean±s.e.m. In vitro experiments were performed
in duplicates and repeated at least three times. For group compa-
risons unpaired t-tests were used, and Mann–Whitney rank-sum
test in case of non-Gaussian distribution. Po0.05 was considered
significant.
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